News

Epigenomics sheds boss
Enlarge image

BusinessGermany

Epigenomics sheds boss

26.09.2012 - The Berlin-based epigenetics specialist Epigenomics AG has changed its CEO with immediate effect.

Thomas Taapken, formerly CFO will replace his boss Geert Nygaard who will leave the company on September 30.  “On behalf of the Board of Directors, I would like to thank Geert Nygaard for his dedication to the Company for the past five and half years", said Heino von Prondzynski, Epigenomics’ Chairman of the Board. Prodzynski, a former Head of Roche Diagnostics, joined the company's board in March this year. He is regarded as a renowned industry expert. Epigenomics has faced several changes in the company's business strategy in the recent years. One year ago, the Berlin-based diagnostics specialist halved its workforce to about 40 staff in the light of a corporate restructuring. Among other things, Epigenomics stopped its own marketing for the Epiprocolon blood test to detect colon cancer in Germany. The focus of the company was turned to the US market where the company runs a clinical study as the basis for a possible FDA approval. The underlying Septin9 marker was out-licensed non-exclusively to a number of partners. However, revenues from this operation do not compensate for the company's development spending. At the end of the second quarter, Epigenomics had €9.1m in cash with a loss of about €5.7m in the first half of 2012

© eurobiotechnews.eu/pd

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3037.3%
  • GW PHARMACEUTICALS (UK)426.00 GBP667.6%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.28 CHF-91.7%
  • THROMBOGENICS (B)9.14 EUR-70.4%

No liability assumed, Date: 30.07.2014